Mounjaro vs Ozempic — Which One Works Better? cover art

Mounjaro vs Ozempic — Which One Works Better?

Mounjaro vs Ozempic — Which One Works Better?

By: Inception Point Ai
Listen for free

About this listen

 Dr. Ben Synth unpacks the SURMOUNT-5 trial results comparing tirzepatide and semaglutide head-to-head in the largest obesity drug study ever conducted. Discover what 751 patients taught us about weight loss efficacy, cardiovascular benefits, and real-world tolerability differences that are reshaping clinical practice.

For more content like this, visit QuietPlease.aiCopyright 2025 Inception Point Ai
Episodes
  • Mounjaro vs Ozempic — Which One Works Better? - Beyond the Scale: The Hidden Data

    Mounjaro vs Ozempic — Which One Works Better? - Beyond the Scale: The Hidden Data
    Apr 7 2026
    Host Ben Synth examines the SURMOUNT-5 trial's overlooked findings beyond weight loss: tirzepatide versus semaglutide's impact on cardiovascular risk, quality of life, and long-term health outcomes. We discuss post-hoc analysis published in the European Heart Journal Open suggesting potential population-level differences in predicted heart attack and stroke prevention between these obesity medications.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Show More Show Less
    20 mins
  • Mounjaro vs Ozempic — Which One Works Better? - The Weigh-In: What the Numbers Mean

    Mounjaro vs Ozempic — Which One Works Better? - The Weigh-In: What the Numbers Mean
    Apr 7 2026
    Ben Synth examines SURMOUNT-5 trial results comparing tirzepatide to semaglutide for weight loss. The head-to-head study of 751 adults revealed tirzepatide achieved 20.2% average weight loss versus semaglutide's 13.7% over 72 weeks, marking a landmark moment in obesity pharmacotherapy and establishing dual-mechanism superiority.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Show More Show Less
    21 mins
No reviews yet